300683 海特生物
已收盘 04-24 15:00:00
资讯
新帖
简况
图解海特生物年报：第四季度单季净利润同比下降147.16%
证券之星 · 04-24 01:56
图解海特生物年报：第四季度单季净利润同比下降147.16%
股市必读：海特生物(300683)股东户数2.06万户，较上期减少3.79%
证券之星 · 04-20
股市必读：海特生物(300683)股东户数2.06万户，较上期减少3.79%
海特生物：沙艾特目前销售情况一切顺利，也符合公司的预期
证券之星 · 04-17
海特生物：沙艾特目前销售情况一切顺利，也符合公司的预期
海特生物：截止3月31日，公司股东人数为21,409户
证券之星 · 04-03
海特生物：截止3月31日，公司股东人数为21,409户
海特生物：截止3月20日，公司股东人数为17,810户
证券之星 · 03-25
海特生物：截止3月20日，公司股东人数为17,810户
海特生物（300683）披露控股股东部分股份质押及解除质押公告，3月23日股价上涨1.56%
证券之星 · 03-23
海特生物（300683）披露控股股东部分股份质押及解除质押公告，3月23日股价上涨1.56%
海特生物（300683）披露对外投资进展公告，3月19日股价下跌5.2%
证券之星 · 03-19
海特生物（300683）披露对外投资进展公告，3月19日股价下跌5.2%
股市必读：海特生物(300683)股东户数1.8万户，较上期增加7.71%
证券之星 · 03-16
股市必读：海特生物(300683)股东户数1.8万户，较上期增加7.71%
海特生物：公司注射用埃普奈明2023年11月获批上市，2024年开始销售，2025年被纳入国家医保目录，目前销售顺利，符合公司预期
证券之星 · 03-13
海特生物：公司注射用埃普奈明2023年11月获批上市，2024年开始销售，2025年被纳入国家医保目录，目前销售顺利，符合公司预期
海特生物(300683)3月10日股东户数1.8万户，较上期增加7.71%
证券之星 · 03-13
海特生物(300683)3月10日股东户数1.8万户，较上期增加7.71%
海特生物：公司中间体、原料药业务近两年因市场竞争加剧，订单不足，目前是公司主要亏损源
每日经济新闻 · 03-13
海特生物：公司中间体、原料药业务近两年因市场竞争加剧，订单不足，目前是公司主要亏损源
海特生物：截止3月10日，公司股东人数为17,968户
证券之星 · 03-12
海特生物：截止3月10日，公司股东人数为17,968户
股市必读：海特生物(300683)股东户数1.67万户，较上期减少1.23%
证券之星 · 03-09
股市必读：海特生物(300683)股东户数1.67万户，较上期减少1.23%
海特生物：截止2月27日，公司股东人数为16,682户
证券之星 · 03-06
海特生物：截止2月27日，公司股东人数为16,682户
海特生物(300683)2月27日股东户数1.67万户，较上期减少1.23%
证券之星 · 03-04
海特生物(300683)2月27日股东户数1.67万户，较上期减少1.23%
海特生物：截止2月27日，公司股东人数为16,682户
证券之星 · 03-03
海特生物：截止2月27日，公司股东人数为16,682户
股市必读：海特生物(300683)股东户数1.81万户，较上期减少6.51%
证券之星 · 02-24
股市必读：海特生物(300683)股东户数1.81万户，较上期减少6.51%
海特生物：截止2026年2月10日，公司股东人数为18,142户
证券之星 · 02-13
海特生物：截止2026年2月10日，公司股东人数为18,142户
新版基药目录管理办法公布；“减肥神药”或能改善骨关节炎
21世纪经济报道 · 02-12
新版基药目录管理办法公布；“减肥神药”或能改善骨关节炎
海特生物最新公告：拟6201.90万元收购北京沙东23.08%股权
证券之星 · 02-11
海特生物最新公告：拟6201.90万元收购北京沙东23.08%股权
加载更多
公司概况
公司名称：
武汉海特生物制药股份有限公司
所属行业：
医药制造业
上市日期：
2017-08-08
主营业务：
武汉海特生物制药股份有限公司的主营业务是大分子生物药、小分子化学药、原料药与医药中间体的生产销售，同时也为国内外的制药企业提供制剂和原料药的CRO、CMO和CDMO技术服务。公司的主要产品是技术服务、注射用鼠神经生长因子、注射用埃普奈明。
发行价格：
32.94
{"stockData":{"symbol":"300683","market":"SZ","secType":"STK","nameCN":"海特生物","latestPrice":32.84,"timestamp":1777014204000,"preClose":32.24,"halted":0,"volume":6133100,"delay":0,"changeRate":0.0186,"floatShares":122000000,"shares":131000000,"eps":-1.8365,"marketStatus":"已收盘","change":0.6,"latestTime":"04-24 15:00:00","open":32.26,"high":33.02,"low":32,"amount":200000000,"amplitude":0.0316,"askPrice":32.84,"askSize":5,"bidPrice":32.83,"bidSize":46,"shortable":0,"etf":0,"ttmEps":-1.8365,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777253400000},"marketStatusCode":5,"adr":0,"adjPreClose":32.24,"symbolType":"stock","openAndCloseTimeList":[[1776994200000,1777001400000],[1777006800000,1777014000000]],"highLimit":35.46,"lowLimit":29.02,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":130894391,"isCdr":false,"pbRate":1.97,"roa":"--","roe":"--","epsLYR":-1.77,"committee":0.205,"marketValue":4299000000,"turnoverRate":0.0502,"status":0,"floatMarketCap":4009000000},"requestUrl":"/m/hq/s/300683","defaultTab":"news","newsList":[{"id":"2629541268","title":"图解海特生物年报：第四季度单季净利润同比下降147.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629541268","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629541268?lang=zh_cn&edition=full","pubTime":"2026-04-24 01:56","pubTimestamp":1776967000,"startTime":"0","endTime":"0","summary":"证券之星消息，海特生物2025年年报显示，当年度公司主营收入5.41亿元，同比下降16.57%；归母净利润-2.31亿元，同比下降233.48%；扣非净利润-2.55亿元，同比下降145.54%；其中2025年第四季度，公司单季度主营收入1.2亿元，同比下降39.62%；单季度归母净利润-7317.31万元，同比下降147.16%；单季度扣非净利润-7472.08万元，同比下降122.8%；负债率15.8%，投资收益2064.35万元，财务费用-472.24万元，毛利率42.64%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400004800.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300683"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628798017","title":"股市必读：海特生物(300683)股东户数2.06万户，较上期减少3.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628798017","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628798017?lang=zh_cn&edition=full","pubTime":"2026-04-20 02:05","pubTimestamp":1776621912,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘，海特生物报收于34.2元，下跌2.92%，换手率7.14%，成交量8.72万手，成交额2.99亿元。股本股东变化股东户数变动近日海特生物披露，截至2026年4月10日公司股东户数为2.06万户，较3月31日减少811.0户，减幅为3.79%。户均持股数量由上期的6114.0股增加至6355.0股，户均持股市值为23.0万元。沙艾特目前销售情况一切顺利，也符合公司的预期。截止4月10日，公司股东人数为20,598户。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000000907.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300683","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628026276","title":"海特生物：沙艾特目前销售情况一切顺利，也符合公司的预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2628026276","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628026276?lang=zh_cn&edition=full","pubTime":"2026-04-17 16:03","pubTimestamp":1776412993,"startTime":"0","endTime":"0","summary":"证券之星消息，海特生物(300683)04月17日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘好，请问目前沙艾特目前在dtp药房渗透率如何，覆盖哪些地区？请及时回复，谢谢海特生物回复：尊敬的投资者您好!沙艾特目前销售情况一切顺利，也符合公司的预期。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041700029262.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300683"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624636909","title":"海特生物：截止3月31日，公司股东人数为21,409户","url":"https://stock-news.laohu8.com/highlight/detail?id=2624636909","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624636909?lang=zh_cn&edition=full","pubTime":"2026-04-03 09:03","pubTimestamp":1775178194,"startTime":"0","endTime":"0","summary":"证券之星消息，海特生物(300683)04月02日在投资者关系平台上答复投资者关心的问题。投资者提问：你好！请问公司3/31号股东户数是多少？谢谢！海特生物回复：尊敬的投资者，您好。截止3月31日，公司股东人数为21,409户。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300009258.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300683"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622046167","title":"海特生物：截止3月20日，公司股东人数为17,810户","url":"https://stock-news.laohu8.com/highlight/detail?id=2622046167","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622046167?lang=zh_cn&edition=full","pubTime":"2026-03-25 11:36","pubTimestamp":1774409778,"startTime":"0","endTime":"0","summary":"证券之星消息，海特生物(300683)03月24日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止3月20日公司股东人数是多少？谢谢！海特生物回复：海特生物：尊敬的投资者，您好。截止3月20日，公司股东人数为17,810户。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032500019561.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300683"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621707852","title":"海特生物（300683）披露控股股东部分股份质押及解除质押公告，3月23日股价上涨1.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621707852","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621707852?lang=zh_cn&edition=full","pubTime":"2026-03-23 22:53","pubTimestamp":1774277596,"startTime":"0","endTime":"0","summary":"公司于近日披露《关于控股股东部分股份质押及解除质押的公告》。公告显示，武汉海特生物制药股份有限公司控股股东武汉三江源投资发展有限公司将其持有的公司5,140,000股股份质押给湖北省新活力上市高质量三号投资合伙企业，占其所持股份比例20.39%，占公司总股本比例3.93%，质押用途为偿还借款。截至公告日，三江源累计质押股份数量为5,140,000股，占其所持股份比例20.39%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300040331.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300683"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620229136","title":"海特生物（300683）披露对外投资进展公告，3月19日股价下跌5.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620229136","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620229136?lang=zh_cn&edition=full","pubTime":"2026-03-19 22:15","pubTimestamp":1773929719,"startTime":"0","endTime":"0","summary":"截至2026年3月19日收盘，海特生物报收于33.21元，较前一交易日下跌5.2%，最新总市值为43.47亿元。该股当日开盘34.98元，最高34.98元，最低33.01元，成交额达1.93亿元，换手率为4.7%。公司于近日披露《关于对外投资的进展公告》。本次变更后，北京沙东注册资本为2293.8792万元，公司类型为其他有限责任公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031900039423.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300683"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619201107","title":"股市必读：海特生物(300683)股东户数1.8万户，较上期增加7.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619201107","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619201107?lang=zh_cn&edition=full","pubTime":"2026-03-16 01:30","pubTimestamp":1773595832,"startTime":"0","endTime":"0","summary":"截至2026年3月13日收盘，海特生物报收于34.46元，下跌9.1%，换手率8.86%，成交量10.82万手，成交额3.81亿元。当日关注点来自交易信息汇总：3月13日主力资金净流出2263.72万元，散户资金净流入2187.22万元。来自股本股东变化：截至2026年3月10日公司股东户数为1.8万户，较前期增长7.71%，户均持股数量下降至7285.0股。股本股东变化股东户数变动近日海特生物披露，截至2026年3月10日公司股东户数为1.8万户，较2月27日增加1286.0户，增幅为7.71%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600000568.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300683"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619700197","title":"海特生物：公司注射用埃普奈明2023年11月获批上市，2024年开始销售，2025年被纳入国家医保目录，目前销售顺利，符合公司预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2619700197","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619700197?lang=zh_cn&edition=full","pubTime":"2026-03-13 20:51","pubTimestamp":1773406317,"startTime":"0","endTime":"0","summary":"证券之星消息，海特生物(300683)03月12日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘好。注射用埃普奈明（沙艾特）销售有一年了，请问目前市场反馈如何？海特生物回复：尊敬的投资者，你好。公司注射用埃普奈明2023年11月获批上市，2024年开始销售，2025年被纳入国家医保目录，目前销售顺利，符合公司预期。具体情况可关注公司的定期报告。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031300038437.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300683"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619604061","title":"海特生物(300683)3月10日股东户数1.8万户，较上期增加7.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619604061","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619604061?lang=zh_cn&edition=full","pubTime":"2026-03-13 17:18","pubTimestamp":1773393515,"startTime":"0","endTime":"0","summary":"证券之星消息，近日海特生物披露，截至2026年3月10日公司股东户数为1.8万户，较2月27日增加1286.0户，增幅为7.71%。在医疗服务行业个股中，海特生物股东户数低于行业平均水平，截至3月10日，医疗服务行业平均股东户数为4.56万户。从股价来看，2026年2月27日至2026年3月10日，海特生物区间涨幅为10.82%，在此期间股东户数增加1286.0户，增幅为7.71%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031300029378.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300683"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619375168","title":"海特生物：公司中间体、原料药业务近两年因市场竞争加剧，订单不足，目前是公司主要亏损源","url":"https://stock-news.laohu8.com/highlight/detail?id=2619375168","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619375168?lang=zh_cn&edition=full","pubTime":"2026-03-13 12:44","pubTimestamp":1773377040,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：公司中间体、原料药业务目前市场竞争激烈吗？还有价格战吗？能达到盈亏平衡吗？海特生物（300683.SZ）3月13日在投资者互动平台表示，公司中间体、原料药业务近两年因市场竞争加剧，订单不足，目前是公司主要亏损源。公司正在积极推进该业务的发展，已做一些技术、产品储备，努力实现该业务的减亏及扭亏。（文章来源：每日经济新闻）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-13/doc-inhqvhtr7926458.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-13/doc-inhqvhtr7926458.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300683","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618909089","title":"海特生物：截止3月10日，公司股东人数为17,968户","url":"https://stock-news.laohu8.com/highlight/detail?id=2618909089","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618909089?lang=zh_cn&edition=full","pubTime":"2026-03-12 11:36","pubTimestamp":1773286600,"startTime":"0","endTime":"0","summary":"证券之星消息，海特生物(300683)03月11日在投资者关系平台上答复投资者关心的问题。投资者提问：你好！请问公司26年3月10日股东户数是多少？谢谢！海特生物回复：尊敬的投资者，您好。截止3月10日，公司股东人数为17,968户。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031200016162.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300683","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618695551","title":"股市必读：海特生物(300683)股东户数1.67万户，较上期减少1.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618695551","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618695551?lang=zh_cn&edition=full","pubTime":"2026-03-09 01:43","pubTimestamp":1772991791,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘，海特生物报收于32.41元，上涨4.45%，换手率3.74%，成交量4.56万手，成交额1.46亿元。来自股本股东变化：截至2026年2月27日股东户数环比下降1.23%，户均持股上升至7846.0股，筹码集中度有所提高。股本股东变化股东户数变动近日海特生物披露，截至2026年2月27日公司股东户数为1.67万户，较2月13日减少207.0户，减幅为1.23%。户均持股数量由上期的7750.0股增加至7846.0股，户均持股市值为26.25万元。截止2月27日，公司股东人数为16,682户。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030900000766.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300683","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617507050","title":"海特生物：截止2月27日，公司股东人数为16,682户","url":"https://stock-news.laohu8.com/highlight/detail?id=2617507050","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617507050?lang=zh_cn&edition=full","pubTime":"2026-03-06 15:06","pubTimestamp":1772780778,"startTime":"0","endTime":"0","summary":"证券之星消息，海特生物(300683)03月06日在投资者关系平台上答复投资者关心的问题。投资者提问：你好！请问公司2/27号股东户数是多少？谢谢！海特生物回复：尊敬的投资者，您好。截止2月27日，公司股东人数为16,682户。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600018720.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300683","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616336495","title":"海特生物(300683)2月27日股东户数1.67万户，较上期减少1.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616336495","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616336495?lang=zh_cn&edition=full","pubTime":"2026-03-04 17:12","pubTimestamp":1772615540,"startTime":"0","endTime":"0","summary":"证券之星消息，近日海特生物披露，截至2026年2月27日公司股东户数为1.67万户，较2月13日减少207.0户，减幅为1.23%。在医疗服务行业个股中，海特生物股东户数低于行业平均水平，截至2月27日，医疗服务行业平均股东户数为4.57万户。从股价来看，2026年2月13日至2026年2月27日，海特生物区间涨幅为4.69%，在此期间股东户数减少207.0户，减幅为1.23%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030400029841.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300683"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616935733","title":"海特生物：截止2月27日，公司股东人数为16,682户","url":"https://stock-news.laohu8.com/highlight/detail?id=2616935733","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616935733?lang=zh_cn&edition=full","pubTime":"2026-03-03 08:52","pubTimestamp":1772499131,"startTime":"0","endTime":"0","summary":"证券之星消息，海特生物(300683)03月02日在投资者关系平台上答复投资者关心的问题。投资者提问：截止2月26号，公司股东户数是多少？谢谢海特生物回复：尊敬的投资者，您好。截止2月27日，公司股东人数为16,682户。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030300007082.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300683"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613213736","title":"股市必读：海特生物(300683)股东户数1.81万户，较上期减少6.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613213736","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613213736?lang=zh_cn&edition=full","pubTime":"2026-02-24 01:27","pubTimestamp":1771867628,"startTime":"0","endTime":"0","summary":"截至2026年2月13日收盘，海特生物报收于31.96元，下跌2.29%，换手率3.41%，成交量4.16万手，成交额1.34亿元。交易信息汇总资金流向2月13日主力资金净流出1211.24万元，占总成交额9.03%；游资资金净流出725.34万元，占总成交额5.41%；散户资金净流入1936.59万元，占总成交额14.44%。股本股东变化股东户数变动近日海特生物披露，截至2026年2月10日公司股东户数为1.81万户，较1月30日减少1264.0户，减幅为6.51%。户均持股数量由上期的6745.0股增加至7215.0股，户均持股市值为24.88万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400007125.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300683","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611190243","title":"海特生物：截止2026年2月10日，公司股东人数为18,142户","url":"https://stock-news.laohu8.com/highlight/detail?id=2611190243","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611190243?lang=zh_cn&edition=full","pubTime":"2026-02-13 09:01","pubTimestamp":1770944470,"startTime":"0","endTime":"0","summary":"证券之星消息，海特生物(300683)02月12日在投资者关系平台上答复投资者关心的问题。投资者提问：你好！请问公司2/10号股东户数是多少？谢谢！海特生物回复：您好，感谢您的关注。截止2026年2月10日，公司股东人数为18,142户。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021300006431.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300683","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610960339","title":"新版基药目录管理办法公布；“减肥神药”或能改善骨关节炎","url":"https://stock-news.laohu8.com/highlight/detail?id=2610960339","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610960339?lang=zh_cn&edition=full","pubTime":"2026-02-12 07:27","pubTimestamp":1770852424,"startTime":"0","endTime":"0","summary":"这里是《21健讯Daily》，欢迎与21世纪经济报道新健康团队共同关注医药健康行业最新事件！政策动向国家卫健委等11部门联合印发《国家基本药物目录管理办法》2月11日，国家卫生健康委等联合印发《国家基本药物目录管理办法》。与原有的文件相比，《国家基本药物目录管理办法》主要修订六个方面：一是增加法律政策依据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602123648366353.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602123648366353.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["601607","LU1580142542.USD","LU2097828805.USD","LU2580892789.USD","BK0188","LU1064130708.USD","LU2580892862.HKD","LU1146622755.USD","LU1064131003.USD","LU1997245177.USD","BK0239","LU1328615791.USD","LU1781817850.SGD","LU0405327148.USD","BK0046","LU2328871848.SGD","BK0028","BK0012","BK0196","BK0097","LU2488822045.USD","LU2097828631.EUR","LU2097828474.EUR","BK0187","BK0070","BK0077","LU2148510915.USD","BK0184","LU1997245094.SGD","300683","LU1997244956.HKD","LU2289578879.USD","BK0099","BK0183","LU2097828714.EUR","LU1255011170.USD","LU1820825898.SGD","300142","BK0060","LU1655091616.SGD","LU2097828557.USD","LU2495084118.USD","BK0209","BK0175","LU0405327494.USD","LU1969619763.USD","600276","301075","BK0020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610982912","title":"海特生物最新公告：拟6201.90万元收购北京沙东23.08%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2610982912","media":"证券之星","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610982912?lang=zh_cn&edition=full","pubTime":"2026-02-11 16:37","pubTimestamp":1770799028,"startTime":"0","endTime":"0","summary":"海特生物(300683.SZ)公告称，公司根据已签订的《股权收购协议书》，拟使用自有资金6201.90万元受让君和企业有限公司、朱冬梅、杨世方、崔俊生、SHA BINGDONG、蔚坷利合计持有的北京沙东23.0816%的股权。交易完成后，公司将持有北京沙东98.8420%的股权。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021100026033.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300683"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1777124922385,"stockEarnings":[{"period":"1week","weight":-0.0398},{"period":"1month","weight":-0.1044},{"period":"3month","weight":-0.0141},{"period":"6month","weight":-0.022},{"period":"1year","weight":0.4576},{"period":"ytd","weight":0.1843}],"compareEarnings":[{"period":"1week","weight":0.007},{"period":"1month","weight":0.0377},{"period":"3month","weight":-0.0136},{"period":"6month","weight":0.0328},{"period":"1year","weight":0.2374},{"period":"ytd","weight":0.028}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"武汉海特生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"20598人(较上一季度减少3.79%)","perCapita":"5926股","listingDate":"2017-08-08","address":"湖北省武汉市蔡甸区经济技术开发区海特科技园","registeredCapital":"13089万元","survey":" 武汉海特生物制药股份有限公司的主营业务是大分子生物药、小分子化学药、原料药与医药中间体的生产销售，同时也为国内外的制药企业提供制剂和原料药的CRO、CMO和CDMO技术服务。公司的主要产品是技术服务、注射用鼠神经生长因子、注射用埃普奈明。","listedPrice":32.94},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海特生物(300683)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海特生物(300683)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海特生物,300683,海特生物股票,海特生物股票老虎,海特生物股票老虎国际,海特生物行情,海特生物股票行情,海特生物股价,海特生物股市,海特生物股票价格,海特生物股票交易,海特生物股票购买,海特生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海特生物(300683)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海特生物(300683)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}